Aileron-logo.png
Aileron Therapeutics to Participate in Fireside Chat at the William Blair Biotech Focus Conference 2021
08 juil. 2021 08h15 HE | Aileron Therapeutics, Inc.
BOSTON, July 08, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer...
Aileron-logo.png
Aileron Therapeutics Announces Initiation of Randomized, Double-Blind, Placebo-Controlled Trial of ALRN-6924 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
01 juil. 2021 08h00 HE | Aileron Therapeutics, Inc.
Phase 1b trial anticipated to enroll 60 patients with advanced p53-mutated NSCLC undergoing chemotherapy with first-line carboplatin plus pemetrexedStudy will evaluate proportion of treatment cycles...
Aileron-logo.png
Aileron Therapeutics to be Added to the Russell Microcap® Index
24 juin 2021 07h00 HE | Aileron Therapeutics, Inc.
BOSTON, June 24, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer...
Aileron-logo.png
Aileron Therapeutics to Host KOL Virtual Investor Event Discussing Opportunity for New Paradigm to Protect Cancer Patients from Chemotherapy-Induced Toxicities
19 mai 2021 07h00 HE | Aileron Therapeutics, Inc.
-- Fireside chat, moderated by Soumit Roy, Ph.D. of JonesTrading, will be held on Wednesday, May 26, 2021 at 11:00 am ET -- -- Featured speakers will include hematologist Alan List, M.D....
Aileron-logo.png
Aileron Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
11 mai 2021 16h18 HE | Aileron Therapeutics, Inc.
Progressing ALRN-6924: on track to initiate Phase 1b randomized placebo-controlled trial in patients with p53-mutated non-small cell lung cancer in 2nd quarter 2021 with early interim read-out...
Aileron-logo.png
Aileron Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights
24 mars 2021 16h36 HE | Aileron Therapeutics, Inc.
2020 marked a year of successful evolution to a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients -- Advancing selective...
Aileron-logo.png
Aileron Therapeutics to Present at 2021 H.C. Wainwright Global Life Sciences Conference
04 mars 2021 08h30 HE | Aileron Therapeutics, Inc.
WATERTOWN, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN) today announced that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will give a corporate...
Aileron-logo.png
Aileron Therapeutics Announces Enrollment Expansion for Upcoming Phase 1b Clinical Trial of ALRN-6924 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
02 mars 2021 07h00 HE | Aileron Therapeutics, Inc.
-- Placebo-controlled trial anticipated to enroll 60 patients with advanced p53-mutated NSCLC undergoing treatment with first-line carboplatin plus pemetrexed -- -- Trial anticipated to begin in...
Aileron-logo.png
Aileron Therapeutics Announces Completion of $35.9 Million Registered Direct Offering with Participation by New Fundamental Healthcare Investors Acorn Bioventures, BVF Partners, L.P. and Maven Investment Partners
11 janv. 2021 06h30 HE | Aileron Therapeutics, Inc.
-- Several existing Aileron investors, including Satter Medical Technology Partners and Lincoln Park Capital Fund, LLC, also participated in the offering -- – Aileron plans to use net proceeds to...
Aileron-logo.png
Aileron Therapeutics Announces $35.9 Million Registered Direct Offering
06 janv. 2021 09h30 HE | Aileron Therapeutics, Inc.
WATERTOWN, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (Nasdaq: ALRN), today announced that it has entered into definitive agreements with fundamental healthcare investors...